| Year |
Citation |
Score |
| 2012 |
Zeitzer JM, Kodama T, Buckmaster CL, Honda Y, Lyons DM, Nishino S, Mignot E. Time-course of cerebrospinal fluid histamine in the wake-consolidated squirrel monkey. Journal of Sleep Research. 21: 189-94. PMID 21910776 DOI: 10.1111/J.1365-2869.2011.00957.X |
0.316 |
|
| 2011 |
Nishino S, Mignot E. Narcolepsy and cataplexy. Handbook of Clinical Neurology. 99: 783-814. PMID 21056228 DOI: 10.1016/B978-0-444-52007-4.00007-2 |
0.317 |
|
| 2010 |
Lammers GJ, Bassetti C, Billiard M, Black J, Broughton R, Dauvilliers Y, Ferini Strambi L, Garcia-Borreguero D, Goswami M, Högl B, Iranzo A, Jennum P, Khatami R, Lecendreux M, Mayer G, Mignot E, et al. Sodium oxybate is an effective and safe treatment for narcolepsy. Sleep Medicine. 11: 105-6; author reply . PMID 19846338 DOI: 10.1016/J.Sleep.2009.08.003 |
0.424 |
|
| 2009 |
Zeitzer JM, Buckmaster CL, Landolt HP, Lyons DM, Mignot E. Modafinil and γ-hydroxybutyrate have sleep state-specific pharmacological actions on hypocretin-1 physiology in a primate model of human sleep. Behavioural Pharmacology. 20: 643-52. PMID 19752724 DOI: 10.1097/Fbp.0B013E328331B9Db |
0.303 |
|
| 2009 |
Tonon C, Franceschini C, Testa C, Manners DN, Poli F, Mostacci B, Mignot E, Montagna P, Barbiroli B, Lodi R, Plazzi G. Distribution of neurochemical abnormalities in patients with narcolepsy with cataplexy: An in vivo brain proton MR spectroscopy study. Brain Research Bulletin. 80: 147-50. PMID 19463917 DOI: 10.1016/J.Brainresbull.2009.05.010 |
0.338 |
|
| 2007 |
Yokogawa T, Marin W, Faraco J, Pézeron G, Appelbaum L, Zhang J, Rosa F, Mourrain P, Mignot E. Characterization of sleep in zebrafish and insomnia in hypocretin receptor mutants. Plos Biology. 5: e277. PMID 17941721 DOI: 10.1371/Journal.Pbio.0050277 |
0.303 |
|
| 2007 |
Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 369: 499-511. PMID 17292770 DOI: 10.1016/S0140-6736(07)60237-2 |
0.309 |
|
| 2006 |
Zeitzer JM, Nishino S, Mignot E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends in Pharmacological Sciences. 27: 368-74. PMID 16766052 DOI: 10.1016/J.Tips.2006.05.006 |
0.309 |
|
| 2005 |
Shepard JW, Buysse DJ, Chesson AL, Dement WC, Goldberg R, Guilleminault C, Harris CD, Iber C, Mignot E, Mitler MM, Moore KE, Phillips BA, Quan SF, Rosenberg RS, Roth T, et al. History of the development of sleep medicine in the United States. Journal of Clinical Sleep Medicine : Jcsm : Official Publication of the American Academy of Sleep Medicine. 1: 61-82. PMID 17561617 |
0.498 |
|
| 2004 |
Mignot E. Sleep, sleep disorders and hypocretin (orexin). Sleep Medicine. 5: S2-8. PMID 15301991 DOI: 10.1016/S1389-9457(04)90001-9 |
0.325 |
|
| 2003 |
Dauvilliers Y, Carlander B, Molinari N, Desautels A, Okun M, Tafti M, Montplaisir J, Mignot E, Billiard M. Month of birth as a risk factor for narcolepsy. Sleep. 26: 663-5. PMID 14572117 DOI: 10.1093/Sleep/26.6.663 |
0.509 |
|
| 2003 |
Vankova J, Stepanova I, Jech R, Elleder M, Ling L, Mignot E, Nishino S, Nevsimalova S. Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep. 26: 427-30. PMID 12841368 DOI: 10.1093/Sleep/26.4.427 |
0.307 |
|
| 2003 |
MartÃnez-RodrÃguez JE, Lin L, Iranzo A, Genis D, Martà MJ, Santamaria J, Mignot E. Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep. 26: 287-90. PMID 12749547 DOI: 10.1093/Sleep/26.3.287 |
0.305 |
|
| 2002 |
Mignot E, Taheri S, Nishino S. Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nature Neuroscience. 5: 1071-5. PMID 12403989 DOI: 10.1038/Nn944 |
0.301 |
|
| 2002 |
Taheri S, Zeitzer JM, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annual Review of Neuroscience. 25: 283-313. PMID 12052911 DOI: 10.1146/Annurev.Neuro.25.112701.142826 |
0.307 |
|
| 2001 |
Mignot E. A commentary on the neurobiology of the hypocretin/orexin system. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 25: S5-13. PMID 11682267 DOI: 10.1016/S0893-133X(01)00316-5 |
0.313 |
|
| 2001 |
Hungs M, Mignot E. Hypocretin/orexin, sleep and narcolepsy. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 23: 397-408. PMID 11340621 DOI: 10.1002/Bies.1058 |
0.329 |
|
| 2000 |
Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. REVIEW ARTICLE. Sleep Medicine Reviews. 4: 57-99. PMID 12531161 DOI: 10.1053/Smrv.1999.0069 |
0.36 |
|
| 2000 |
Nishino S, Riehl J, Hong J, Kwan M, Reid M, Mignot E. Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neuroscience Research. 38: 437-46. PMID 11164570 DOI: 10.1016/S0168-0102(00)00195-4 |
0.3 |
|
| 2000 |
Hong SC, Hayduk R, Lim J, Mignot E. Clinical and polysomnographic features in DQB1*0602 positive and negative narcolepsy patients: results from the modafinil clinical trial. Sleep Medicine. 1: 33-39. PMID 10733618 DOI: 10.1016/S1389-9457(99)00007-6 |
0.302 |
|
| 2000 |
Hungs M, Mignot E. Pathophysiological and clinical aspects of narcolepsy: A disorder associated with hypocretin abnormalities Somnologie. 4: 111-116. |
0.322 |
|
| 1999 |
Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 98: 365-76. PMID 10458611 DOI: 10.1016/S0092-8674(00)81965-0 |
0.312 |
|
| 1999 |
Mignot E, Young T, Lin L, Finn L. Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. Sleep. 22: 347-52. PMID 10341385 |
0.304 |
|
| 1999 |
Faraco J, Lin X, Li R, Hinton L, Lin L, Mignot E. Genetic studies in narcolepsy, a disorder affecting REM sleep. The Journal of Heredity. 90: 129-32. PMID 9987919 DOI: 10.1093/Jhered/90.1.129 |
0.308 |
|
| 1998 |
Nishino S, Mao J, Sampathkumaran R, Shelton J, Mignot E. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants Sleep Research Online. 1: 49-61. PMID 11382857 |
0.303 |
|
| 1998 |
Riehl J, Nishino S, Cederberg R, Dement WC, Mignot E. Development of cataplexy in genetically narcoleptic Dobermans. Experimental Neurology. 152: 292-302. PMID 9710528 DOI: 10.1006/Exnr.1998.6847 |
0.44 |
|
| 1998 |
Reid MS, Nishino S, Tafti M, Siegel JM, Dement WC, Mignot E. Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. Experimental Neurology. 151: 89-104. PMID 9582257 DOI: 10.1006/Exnr.1998.6787 |
0.59 |
|
| 1998 |
Kadotani H, Faraco J, Mignot E. Genetic studies in the sleep disorder narcolepsy. Genome Research. 8: 427-34. PMID 9582188 DOI: 10.1101/Gr.8.5.427 |
0.309 |
|
| 1998 |
Cederberg R, Nishino S, Dement WC, Mignot E. Breeding history of the Stanford colony of narcoleptic dogs. The Veterinary Record. 142: 31-6. PMID 9481825 DOI: 10.1136/Vr.142.2.31 |
0.447 |
|
| 1997 |
Nishino S, Tafti M, Sampathkumaran R, Dement WC, Mignot E. Circadian distribution of rest/activity in narcoleptic and control dogs: assessment with ambulatory activity monitoring. Journal of Sleep Research. 6: 120-7. PMID 9377531 |
0.629 |
|
| 1997 |
Nishino S, Arrigoni J, Shelton J, Kanbayashi T, Dement WC, Mignot E. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 6401-8. PMID 9236248 |
0.516 |
|
| 1997 |
Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Progress in Neurobiology. 52: 27-78. PMID 9185233 DOI: 10.1016/S0301-0082(96)00070-6 |
0.309 |
|
| 1997 |
Mignot E, Kimura A, Lattermann A, Lin X, Yasunaga S, Mueller-Eckhardt G, Rattazzi C, Lin L, Guilleminault C, Grumet FC, Mayer G, Dement WC, Underhill P. Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens. 49: 329-41. PMID 9151385 DOI: 10.1111/J.1399-0039.1997.Tb02761.X |
0.434 |
|
| 1997 |
Tafti M, Nishino S, Liao W, Dement WC, Mignot E. Mesopontine organization of cholinergic and catecholaminergic cell groups in the normal and narcoleptic dog. The Journal of Comparative Neurology. 379: 185-97. PMID 9050784 DOI: 10.1002/(Sici)1096-9861(19970310)379:2<185::Aid-Cne2>3.0.Co;2-# |
0.595 |
|
| 1996 |
Mignot E. Perspectives in narcolepsy research and therapy. Current Opinion in Pulmonary Medicine. 2: 482-7. PMID 9363189 |
0.327 |
|
| 1996 |
Kanbayashi T, Nishino S, Tafti M, Hishikawa Y, Dement WC, Mignot E. Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. Neuroreport. 7: 1881-6. PMID 8905685 DOI: 10.1097/00001756-199608120-00002 |
0.644 |
|
| 1996 |
Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel JM, Mignot E. Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. Brain Research. 733: 83-100. PMID 8891251 DOI: 10.1016/0006-8993(96)00541-0 |
0.484 |
|
| 1996 |
Kanbayashi T, Nishino S, Tafti M, Hishikawa Y, Dement WC, Mignot E. Thalidomide, immune modulation and narcolepsy. Sleep. 19: 116. PMID 8855033 DOI: 10.1093/Sleep/19.2.116 |
0.544 |
|
| 1996 |
Singh SM, George CF, Ott RN, Rattazzi C, Guilleminault C, Dement WC, Mignot E. IgH (mu-switch and gamma-1) region restriction fragment length polymorphism in human narcolepsy. Journal of Clinical Immunology. 16: 208-15. PMID 8840222 DOI: 10.1007/Bf01541226 |
0.431 |
|
| 1996 |
Tafti M, Nishino S, Aldrich MS, Liao W, Dement WC, Mignot E. Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in canine model. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 4588-95. PMID 8764647 DOI: 10.1523/Jneurosci.16-15-04588.1996 |
0.574 |
|
| 1995 |
Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep. 18: 817-26. PMID 8746387 |
0.484 |
|
| 1995 |
Nishino S, Shelton J, Renaud A, Dement WC, Mignot E. Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy. The Journal of Pharmacology and Experimental Therapeutics. 272: 1170-5. PMID 7891329 |
0.517 |
|
| 1995 |
Mignot E, Tafti M, Dement WC, Grumet FC. Narcolepsy and immunity. Advances in Neuroimmunology. 5: 23-37. PMID 7795891 DOI: 10.1016/0960-5428(94)00043-N |
0.633 |
|
| 1995 |
Nishino S, Tafti M, Reid MS, Shelton J, Siegel JM, Dement WC, Mignot E. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 15: 4806-14. PMID 7623112 DOI: 10.1523/Jneurosci.15-07-04806.1995 |
0.659 |
|
| 1994 |
Reid MS, Siegel JM, Dement WC, Mignot E. Cholinergic mechanisms in canine narcolepsy--II. Acetylcholine release in the pontine reticular formation is enhanced during cataplexy. Neuroscience. 59: 523-30. PMID 8008206 DOI: 10.1016/0306-4522(94)90174-0 |
0.479 |
|
| 1994 |
Reid MS, Tafti M, Geary JN, Nishino S, Siegel JM, Dement WC, Mignot E. Cholinergic mechanisms in canine narcolepsy--I. Modulation of cataplexy via local drug administration into the pontine reticular formation. Neuroscience. 59: 511-22. PMID 8008205 DOI: 10.1016/0306-4522(94)90173-2 |
0.605 |
|
| 1994 |
Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 17: 436-7. PMID 7991954 |
0.366 |
|
| 1994 |
Reid MS, Tafti M, Nishino S, Siegel JM, Dement WC, Mignot E. Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. Sleep. 17: 424-35. PMID 7991953 DOI: 10.1093/Sleep/17.5.424 |
0.605 |
|
| 1994 |
Nishino S, Reid MS, Dement WC, Mignot E. Neuropharmacology and neurochemistry of canine narcolepsy. Sleep. 17: S84-92. PMID 7701206 DOI: 10.1093/Sleep/17.Suppl_8.S84 |
0.537 |
|
| 1994 |
Mignot E, Bell RA, Rattazzi C, Lovett M, Grumet FC, Dement WC. An immunoglobulin switchlike sequence is linked with canine narcolepsy. Sleep. 17: S68-76. PMID 7701203 DOI: 10.1093/Sleep/17.Suppl_8.S68 |
0.395 |
|
| 1994 |
Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmayer J, Underhill P, Guilleminault C, Dement WC, Grumet FC. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep. 17: S60-7. PMID 7701202 DOI: 10.1093/Sleep/17.Suppl_8.S60 |
0.402 |
|
| 1993 |
Mignot EJ, Dement WC. Narcolepsy in animals and man. Equine Veterinary Journal. 25: 476-7. PMID 8275992 |
0.385 |
|
| 1993 |
Nishino S, Arrigoni J, Shelton J, Dement WC, Mignot E. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep. 16: 706-12. PMID 8165384 DOI: 10.1093/Sleep/16.8.706 |
0.411 |
|
| 1992 |
Mignot E, Lin X, Kalil J, George C, Singh S, Billiard M, Montplaisir J, Arrigoni J, Guilleminault C, Dement WC. DQB1-0602 (DQw1) is not present in most nonDR2 Caucasian narcoleptics. Sleep. 15: 415-22. PMID 1455124 DOI: 10.1093/SLEEP/15.5.415 |
0.455 |
|
| 1992 |
Valtier D, Dement WC, Mignot E. Monoaminergic uptake in synaptosomes prepared from frozen brain tissue samples of normal and narcoleptic canines. Brain Research. 588: 115-9. PMID 1393561 DOI: 10.1016/0006-8993(92)91350-N |
0.397 |
|
| 1992 |
Dement W, Mignot E. Can narcolepsy be eradicated in this millennium? Loss, Grief and Care. 5: 193-203. DOI: 10.1300/J132v05n03_19 |
0.401 |
|
| 1991 |
Renaud A, Nishino S, Dement WC, Guilleminault C, Mignot E. Effects of SDZ NVI-085, a putative subtype-selective alpha 1-agonist, on canine cataplexy, a disorder of rapid eye movement sleep. European Journal of Pharmacology. 205: 11-6. PMID 1687464 DOI: 10.1016/0014-2999(91)90763-G |
0.516 |
|
| 1991 |
Mignot E, Wang C, Rattazzi C, Gaiser C, Lovett M, Guilleminault C, Dement WC, Grumet FC. Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment. Proceedings of the National Academy of Sciences of the United States of America. 88: 3475-8. PMID 1673032 DOI: 10.1073/Pnas.88.8.3475 |
0.465 |
|
| 1991 |
Valtier D, Nishino S, Guilleminault C, Dement WC, Mignot E. Platelet alpha 2 adrenoceptors in human and canine narcolepsy. Biological Psychiatry. 29: 376-82. PMID 1645207 DOI: 10.1016/0006-3223(91)90223-9 |
0.416 |
|
| 1989 |
Nishino S, Mignot E, Fruhstorfer B, Dement WC, Hayaishi O. Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy. Proceedings of the National Academy of Sciences of the United States of America. 86: 2483-7. PMID 2928344 DOI: 10.1073/Pnas.86.7.2483 |
0.469 |
|
| 1989 |
Mignot E, Bowersox SS, Maddaluno J, Dement W, Ciaranello R. Evidence for multiple [3H]prazosin binding sites in canine brain membranes. Brain Research. 486: 56-66. PMID 2541871 DOI: 10.1016/0006-8993(89)91277-8 |
0.385 |
|
| 1988 |
Mignot E, Guilleminault C, Bowersox S, Rappaport A, Dement WC. Role of central alpha-1 adrenoceptors in canine narcolepsy. The Journal of Clinical Investigation. 82: 885-94. PMID 2843574 DOI: 10.1172/Jci113694 |
0.425 |
|
| 1988 |
Mignot E, Guilleminault C, Bowersox S, Rappaport A, Dement WC. Effect of alpha 1-adrenoceptors blockade with prazosin in canine narcolepsy. Brain Research. 444: 184-8. PMID 2834022 DOI: 10.1016/0006-8993(88)90927-4 |
0.459 |
|
| Show low-probability matches. |